Article Figures & Data
Tables
- Table 1.
Demographic and clinical characteristics of the 15 study patients with adult-onset Still’s disease treated with tocilizumab.
Characteristic n (%) or Mean ± SD Men 9 (60) Age, yrs 33 ± 12 Disease duration, yrs 9 ± 11 Arthralgias 15 (100) Fever 9 (60) Rash 7 (46) Sore throat 3 (20) Pleuritis 3 (20) Mean prednisone dosage, mg/d 27.6 ± 26.3 DMARD, n (mean) 3.6 (range 1–7) Previous treatment with ≥ 1 TNF-α blocker 10 (66) -
DMARD: disease-modifying antirheumatic drug; TNF: tumor necrosis factor.
-
- Table 2.
Effect of tocilizumab (TCZ) on clinical and laboratory measures of Still’s disease activity after 6 months of treatment and at the end of followup. Values are mean ± SD.
Before TCZ After 6 Months TCZ End of Followup Tender joints, n 11.6 ± 6.8 2 ± 1.8* 1.4 ± 2.1* Swollen joints, n 8.6 ± 5.4 1.09 ± 1.6* 0.7 ± 1.5* Fever, n 9 0* 0* Prednisone dosage, mg/d 27.6 ± 26.3 4.9 ± 4* 3.8 ± 4.9* ESR, mm/h 60 ± 28 3.9 ± 1.4* 4.5 ± 1.9* CRP, mg/dl 11.6 ± 15 0.5 ± 0.1* 0.5 ± 0.5* -
↵* Statistically significant, p < 0.05. ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.
-
In this issue
Tocilizumab in Adult-onset Still’s Disease: the Israeli Experience
